---
title: "Fecal Microbiota Transplantation - 2021 Update"
subtitle: "2021 Update"  
author: "Brendan J. Kelly, MD, MS"
date: "`r format(Sys.Date(), '%d %B %Y')`"
output:
  xaringan::moon_reader:
    css: xaringan-themer-blue-grids-fade.css
    lib_dir: libs
    chakra: libs/remark-latest.min.js
    seal: false
    nature:
      ratio: 16:9
      highlightStyle: github
      highlightLines: true
      countIncrementalSlides: false
      slideNumberFormat: "%current%"

---
exclude: true
```{r setup, include=FALSE}
options(htmltools.dir.version = FALSE)
xaringan::summon_remark()
```

```{r xaringan-tile-view, echo=FALSE, message=FALSE, error=FALSE, include=FALSE, comment=FALSE}
xaringanExtra::use_tile_view()
xaringanExtra::use_webcam()
xaringanExtra::use_tachyons()
xaringanExtra::use_animate_css()
xaringanExtra::use_share_again()
```

---
background-image: url(img/cdiff_flip_dark.png)
background-size: cover
class: middle left hide-count

.fade-in[
# <span style='color:white'>Fecal Microbiota Transplantation</span>
]
.fade-in[
.callout-url-leftcorner[
<span style='font-size:0.75em;font-weight:bold;color:white'>
Brendan J. Kelly, MD, MS  
Infectious Diseases & Epidemiology  
University of Pennsylvania  
</span>
<span style='font-size:0.5em;font-weight:bold;color:white;'>
`r format(Sys.Date(), '%d %B %Y')`
</span>
]
]

---

# Disclosures  

.pad-left[

- None  
  
]



---
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a animated flipInY"><div>What & Why?</div></div>
</div>


---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a"><div>What & Why?</div></div>
<div class="extension-tile gridset-b animated flipInX"><div>FMT @Penn</div></div>
</div>


---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a"><div>What & Why?</div></div>
<div class="extension-tile gridset-b"><div>FMT @Penn</div></div>
<div class="extension-tile gridset-c animated bounceInDown"><div>Applications<br>in Oncology</div></div>
</div>



---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a"><div>What & Why?</div></div>
<div class="extension-tile gridset-grey"><div>FMT @Penn</div></div>
<div class="extension-tile gridset-grey"><div>Applications<br>in Oncology</div></div>
</div>



---

# Fecal Microbiota Transplantation (FMT)

.pad-left[

- Transplant fecal microbiota from healthy donor to colon of recipient  
  
- <u>Methods</u>: frozen oral capsules, solution via enteric tube, enema, colonoscopy  

- <u>Indications</u>:

    - _C. difficile_ infection (CDI) = driving force behind development  
    
    - MDRO colonization    
    
    - inflammatory bowel disease (IBD)  
    
    - oncology: auto-FMT post allo-SCT; immune checkpoint inhibitors; GVHD  


]


---

# _Clostridioides difficile_ Infection

.pad-left[

- Infectious colitis that occurs after antibiotic treatment ("antibiotic-associated")  

- Depletion of protective taxa (abx & PPI) ⇾ altered bile acid metabolism ⇾ germination of resident or recently ingested _C. difficile_ spores ⇾ expansion of vegetative _C. difficile_ ⇾ toxin production ⇾ colonic inflammation ⇾ CDI

- Treatment with anti-CDI antibiotics (vancomycin, fidaxomicin) contributes to persistent depletion of protective taxa ⇾ risk for recurrent CDI

- **FMT restores colonization resistance by restoring protective taxa**

- <u>Note</u>: treatment with anti-CDI antibiotics is prerequisite

]


---
background-image: url(img/tariq_2fmt_forest_plot.png)
background-size: 900px
background-position: 50% 35%


.footnote[Tariq R et al _Clin Inf Dis_ 2019]



---
background-image: url(img/cdiff_idsa_guideline_2017_fmt.png)
background-size: 900px
background-position: 50% 35%


.footnote[IDSA/SHEA Guidelines: McDonald LC et al _Clin Inf Dis_ 2018]


---

# Efficacy Despite Product Heterogeneity?

.pad-left[

- FMT contains multitudes:  

    - bacteria, fungi, archaea... bacteriophage, eukaryotic viruses (e.g., TTVs) ...
    
     ... human colonocytes, metabolites

- Causal models for efficacy versus _C. difficile_ infection:  

    - Direct bacterial interaction? Bile acid metabolism-mediated interaction?  

    - Bile acid metabolism & Th17 regulatory cells?  

- **We do it because it works, but we don't know why!**

]

.footnote[Bojanova & Bordenstein _PLoS Biology_ 2016; Ott et al _Gastroenterology_ 2017; Hang et al _Nature_ 2019]


---

# FMT Regulation & Commercial Alternatives

.pad-left[

- **Guideline-recommended for CDI but no FDA-approved product**:

    - IND required for non-CDI indications

    - for CDI, FDA exercises "enforcement discretion"

    - concern that product availability (e.g., OpenBiome) limiting RCT enrollment

- Multiple companies with "ecobiotic" FMT alternatives in phase 2/3 trials:  

    - Finch, Rebiotix, Seres, Vedanta  
    
    - May 2020: "Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial"


]


---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-grey"><div>What & Why?</div></div>
<div class="extension-tile gridset-b animated flipInY"><div>FMT @Penn</div></div>
<div class="extension-tile gridset-grey"><div>Applications<br>in Oncology</div></div>
</div>


---

# FMT Program Development at Penn

.pad-left[

- <u>2014-2016</u>: ID Division Stool Bank  

    - FDA enforcement discretion (no IND)
    
    - 67 FMTs: 82% aggregate cure rate
  
- <u>2016-2018</u>: OpenBiome partnership  

- <u>2019-present</u>: "Penn Microbiome Therapy (PMT)"  

    - IND for 3 products: capsule, upper GI liquid, enema  
    
    - 3 protocols: R-CDI, SC-CDI, postpartum incontinence (OB-GYN: Uduak Andy, PI)  
    
      (compassionate use for MDRO colonization)

]


---

# Impact of COVID-19 on FMT at Penn

.pad-left[

- **FDA partial hold**: all doses manufactured after December 1, 2019

- Adequate donor/dose screening:

    - challenges with stool testing for SARS-CoV-2 (high LOD)
    
    - donor screening with serology? NP NAAT?

- Ongoing COVID-19 activity slows (already slow) clinical trial enrollment

- **Recent resumption of enrollment for all protocols**

]



---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-grey animated"><div>What & Why?</div></div>
<div class="extension-tile gridset-grey animated"><div>FMT @Penn</div></div>
<div class="extension-tile gridset-c animated flipInX"><div>Applications<br>in Oncology</div></div>
</div>



---
background-image: url(img/peled_nejm_2020.png)
background-size: 1000px
background-position: 50% 60%

# Dysbiosis & Death


.footnote[Peled et al _NEJM_ 2020]



---
background-image: url(img/taur_diversity_vs_engraftment.png)
background-size: 800px
background-position: 50% 50%

# Auto-FMT Post Allo-SCT

.footnote[Taur et al _Sci Trans Med_ 2018]


---
background-image: url(img/taur_fmt_taxa.png)
background-size: 600px
background-position: 50% 60%


.footnote[Taur et al _Sci Trans Med_ 2018]


---

# FMT & Immune Checkpoint Inhibitors

.pad-left[

- Differential bacterial signatures of ICI responders versus non-responders

- Modulation of the gut microbiome via FMT from patients alters antitumor immunity and response to ICI therapy in gnotobiotic mice

- FMT also applied to & resolves ICI-related colitis: 

    - variable (donor-dependent) effects on microbiome  
    
    - increase proportion of regulatory T-cells in colonic mucosa  

]
    
.footnote[Routy et al _Science_ 2018; Gopalakrishnan et al _Science_ 2018; Matson et al _Science_ 2018; Wang et al _Nat Med_ 2018]


---

# FMT & GVHD  

.pad-left[

- Disruption of intestinal microbiota associated with GVHD

- Recent prospective single-arm study:  

    - 15 post-allo-HCT with steroid-dependent, acute or late-onset acute intestinal GvHD

    - effect of donor FMT on GVHD symptoms and biomarkers  
    
    - 10 of 15 study participants with complete clinical response observed within 1 month after FMT, without additional interventions to alleviate GVHD symptoms
    
    - associated increase in gut microbial alpha-diversity, a partial engraftment of donor bacterial species, and increased abundance of butyrate-producing bacteria, including _Clostridiales_ and _Blautia_ species
    
]
    
.footnote[van Lier et al _Sci Trans Med_ 2020]



---

# Risks of FMT in Oncology Patients  

.pad-left[

- Disseminated bacterial infection:

    - ESBL _E. coli_ sepsis and death*  
    
- CMV & EBV:

    - CMV colitis post-FMT has been reported  
    
    - risk of CMV listed on informed consent for our PMT prooducts
    
      (donors are screened for CMV/EBV but not restricted)

- GVHD: given heterogeneity of FMT, potential for exacerbation?  
  
]

.footnote[*DeFilipp et al _NEJM_ 2019]



---
class: middle center hide-count
background-image: url(img/cdiff_flip_dark.png)
background-size: cover

# <span style='color:white'>Questions?</span>

 <!-- .callout-url-bottom[  
.fade-in[<span style="font-size:0.5em; color:white">slides ↓ </span>]  
<span style="link-color:white">[bjklab.org](http://www.bjklab.org)</span>  
] --> 


